STOCKHOLM, April 25, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the inclusion of patients with complete spinal cord injury in the first panel has been completed in the company's ongoing clinical Phase 1/2 study. BioArctic develops a new...
from PR Newswire: //https://ift.tt/2FfIhNB
No comments:
Post a Comment